I fear I did not answer your question. In view of our tenuous grasp on reality, that is hard to do. My doubts concerned more the concept of more known=less unknown.
With insider sales thriving in the face of wonderful expectations I am confused, as I have said.
Why using cash to buy a struggling, post-patent ATRS when Halozyme‘s prospects and patent situation was great is also confusing. Injectors are mostly out of patent protection, if the business is any good the Chinese and Indians will not be timid, nor high cost producers.
Halozyme’s own patent and royalty situation is difficult to have certainty about.
The debt to equity conversion, with probable stock liquidation and/or hedging is not “more you know”.
I am not sure whether he falls into the “proto fascist” category or not, but I give credence to Jamie Dimon’s take on the economy and the market. Larry Summers, also reported to be knowledgeable, likewise merits attention.
So, what is my take on Halozyme? Take your pick from the above. To say that “Helen is bullish” is not “more you know”. What else would one expect, Heaven bless her?
Stocks, practically all in institutional hands, don’t just go around helter-skelter tanking 50%. This is not “more you know”.
The less I know, the more I don’t know? When that happens, I look at opportunities elsewhere. They exist.